Collectively, these results suggest that CTSV is localised to the nuclear compartment in breast cancer cells and that targeting CTSV may have potential application to reduce tumour growth by impairing cell cycle progression for ER+ breast cancer. The gene discussed is CTSV; the disease is breast carcinoma.